Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “GD2 Antibody”

29 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 29 results

Early research (Phase 1)Study completedNCT00492167
What this trial is testing

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center 45
Early research (Phase 1)Ended earlyNCT01123304
What this trial is testing

Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma

Who this might be right for
Melanoma
Morphotek 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06948994
What this trial is testing

A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma

Who this might be right for
NeuroblastomaGD2 AntibodyAutologous NK Cell
Guangzhou Women and Children's Medical Center 15
Testing effectiveness (Phase 2)UnknownNCT02173093
What this trial is testing

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

Who this might be right for
Disseminated NeuroblastomaRecurrent Neuroblastoma
University of Virginia 40
Not applicableStudy completedNCT02100930
What this trial is testing

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center 69
Not applicableLooking for participantsNCT06574698
What this trial is testing

Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

Who this might be right for
NeuroblastomaGD2 Antibody (Naxitamab)
Guangzhou Women and Children's Medical Center 64
Early research (Phase 1)Study completedNCT00037011
What this trial is testing

Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center
Not applicableStudy completedNCT00597272
What this trial is testing

Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 34
Not applicableStudy completedNCT01418495
What this trial is testing

Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma

Who this might be right for
Localized Resectable NeuroblastomaLocalized Unresectable NeuroblastomaNeurotoxicity Syndrome+4 more
National Cancer Institute (NCI) 12
Early research (Phase 1)Study completedNCT00003022
What this trial is testing

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

Who this might be right for
Brain and Central Nervous System TumorsIntraocular MelanomaLung Cancer+4 more
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Study completedNCT00877110
What this trial is testing

Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Who this might be right for
NeuroblastomaBone Marrow, Sympathetic Nervous System
Memorial Sloan Kettering Cancer Center 71
Testing effectiveness (Phase 2)Ended earlyNCT03860207
What this trial is testing

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Who this might be right for
NeuroblastomaOsteosarcomaOther Solid Tumor Cancers
Y-mAbs Therapeutics 12
Early research (Phase 1)Study completedNCT01419834
What this trial is testing

Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center 68
Early research (Phase 1)Study completedNCT01576692
What this trial is testing

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Who this might be right for
Neuroblastoma
St. Jude Children's Research Hospital 34
Testing effectiveness (Phase 2)Study completedNCT00089258
What this trial is testing

Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center 74
Early research (Phase 1)Study completedNCT02650648
What this trial is testing

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Who this might be right for
NeuroblastomaHigh-Risk
Memorial Sloan Kettering Cancer Center 85
Early research (Phase 1)Study completedNCT00743496
What this trial is testing

A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma

Who this might be right for
NeuroblastomaMelanomaOsteosarcoma+1 more
St. Jude Children's Research Hospital 50
Testing effectiveness (Phase 2)Study completedNCT00072358
What this trial is testing

Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center 291
Testing effectiveness (Phase 2)Study completedNCT00004184
What this trial is testing

Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma

Who this might be right for
Melanoma (Skin)
University of Alabama at Birmingham 50
Early research (Phase 1)Looking for participantsNCT06641908
What this trial is testing

Anti-GD2 ADC M3554 in Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
EMD Serono Research & Development Institute, Inc. 65
Next Page